This article is more than 5 years old. Information may no longer be current.
CRUISE, BRAVO studies show benefit of anti-VEGF in retinal vein occlusion
Click Here to Manage Email Alerts
KOLOA, Hawaii — Two large-scale randomized clinical trials demonstrate that anti-VEGF therapy significantly improves vision in patients with central or branch retinal vein occlusion, according to a speaker here.
 Linda A. Lam |
In the CRUISE study, 130 patients who received a 0.5-mg dose of Lucentis (ranibizumab, Genentech) in six monthly doses had a mean gain of 14.9 ETDRS letters from baseline and 132 patients in the 0.3-mg group had a mean gain of 12.7 letters from baseline, Linda A. Lam, MD, said at Retina 2010. Patients in the sham arm of the study had a 0.8 letter gain at 6 months, she said. Overall, 47.7%, 46.2% and 16.9%, respectively, gained 15 or more letters at 6 months.
"There was no increased risk of ocular or systemic adverse events compared with previous phase 3 studies of Lucentis," Dr. Lam said.
The BRAVO study showed a similar benefit for ranibizumab therapy for BRVO. In that study, there was a mean change in visual acuity of 18.3 ETDRS letters among 131 patients, 16.6 letters among 134 patients and 7.3 letters among 132 patients in the 0.5-mg, 0.3-mg and sham groups, respectively. Overall, 61.9%, 55.2% and 28.8%, respectively, gained 15 or more letters.
The safety profile was similar to the CRUISE study on CRVO, Dr. Lam said.
Hawaiian Eye and Retina 2011 will be held January 16-21, 2011 at the Hyatt Regency Maui Resort & Spa in Ka'anapali, Maui. Learn more at OSNHawaiianEye.com.